Modality
Gene Therapy
MOA
Anti-Tau
Target
PD-L1
Pathway
DDR
SchizophreniaRett
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Mar 2025
Phase 1Current
NCT03469082
2,289 pts·Rett
2021-03→2025-03·Completed
NCT03266286
1,172 pts·Rett
2023-03→TBD·Active
3,461 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-03-061.1y agoPh2 Data· Rett
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P1/2
Complet…
P1/2
Active
Catalysts
Ph2 Data
2025-03-06 · 1.1y ago
Rett
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03469082 | Phase 1/2 | Rett | Completed | 2289 | CfB |
| NCT03266286 | Phase 1/2 | Rett | Active | 1172 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Polatuximab | Nuvalent | Approved | PD-L1 |